Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 49, Issue 1, Pages 307-317Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm050644n
Keywords
-
Categories
Funding
- NINDS NIH HHS [R01 NS020036, NS20036, R01 NS020036-18] Funding Source: Medline
Ask authors/readers for more resources
Pro-Leu-Gly-NH2 (PLG), in addition to its endocrine effects, possesses the ability to modulate dopamine D-2 receptors within the central nervous system. However, the precise binding site of PLG is unknown. Potential photoaffinity-labeling ligands of the PLG binding site were designed as tools to be used in the identification of the macromolecule that possesses this binding site. Six different photoaffinity-labeling ligands were designed and synthesized on the basis of the gamma-lactam PLG peptidomimetic 1. The 4-azidobenzoyl and 4-azido-2-hydroxybenzoyl photoaffinity-labeling moieties were placed at opposite ends of PLG peptidomimetic I to generate a series of ligands that potentially could be used to map the PLG binding site. All of the compounds that were synthesized possessed activity comparable to or better than PLG in enhancing [H-3]-N-propylnorapomorphine agonist binding to dopamine receptors. Photoaffinity ligands that were crosslinked to the receptor preparation produced a modulatory effect that was either comparable to or greater than the increase in agonist binding produced by the respective ligands that were not cross-linked to the dopamine receptor. The results indicate that these photoaffinity-labeling agents are binding at the same allosteric site as PLG and PLG peptidomimetic 1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available